REVENUE INTEREST FINANCING AGREEMENT among ALLURION TECHNOLOGIES, INC. and RTW MASTER FUND, LTD., RTW INNOVATION MASTER FUND, LTD., and RTW VENTURE FUND LIMITED Dated February 9, 2023Revenue Interest Financing Agreement • February 9th, 2023 • Compute Health Acquisition Corp. • Blank checks • New York
This Revenue Interest Financing Agreement (this “Agreement”) dated as of February 9, 2023 (the “Effective Date”) is among Allurion Technologies, Inc., a Delaware corporation (the “Company”), and RTW Master Fund, Ltd., an exempted company incorporated in the Cayman Islands with limited liability, RTW Innovation Master Fund, Ltd., an exempted company incorporated in the Cayman Islands with limited liability, and RTW Venture Fund Limited, an investment company limited by shares incorporated under the laws of Guernsey (each and collectively, the “Investor”). Each of the Company and the Investor is referred to in this Agreement as a “Party” and collectively as the “Parties”.
SECOND AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENTRevenue Interest Financing Agreement • March 13th, 2024 • Liquidia Corp • Pharmaceutical preparations
This SECOND AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT, dated as of June 28, 2023 (this “Amendment”), is entered into by and between Liquidia Technologies, Inc., a Delaware corporation (the “Company”), and Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership, as the sole Investor and Investor Representative under the Agreement (as defined below) (the “Investor Representative”), solely with respect to certain enumerated provisions in the Agreement described herein. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.
REVENUE INTEREST FINANCING AGREEMENT Dated as of April 19, 2022 between BIOXCEL THERAPEUTICS, INC., THE PURCHASERS FROM TIME TO TIME PARTY HERETO, and OAKTREE FUND ADMINISTRATION, LLC, as the Administrative AgentRevenue Interest Financing Agreement • August 11th, 2022 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • New York
This REVENUE INTEREST FINANCING AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of April 19, 2022, by and between BioXcel Therapeutics, Inc., a Delaware corporation (the “Company”), the entities listed in Schedule 1 hereto (the “Purchasers”), and Oaktree Fund Administration, LLC, as administrative agent for the Purchasers (in such capacity, the “Administrative Agent” and, together with the Company and the Purchasers, the “Parties”, and each a “Party”).
FIRST AMENDMENT TO REVENUE INTEREST FINANCING AGREEMENTRevenue Interest Financing Agreement • June 6th, 2024 • Marinus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS FIRST AMENDMENT TO REVENUE INTEREST FINANCING AGREEMENT (this “Amendment”) is entered into as of June 6, 2024, by and between MARINUS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and Sagard Healthcare Partners FUNDING Borrower SPE 1, lp, a Delaware limited partnership (as successor in interest by assignment to Sagard Healthcare Partners (Delaware) LP, a Delaware limited partnership (as successor in interest by assignment to Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempted limited partnership)) (the “Investor”).
REVENUE INTEREST FINANCING AGREEMENT among ALLURION TECHNOLOGIES, LLC and RTW MASTER FUND, LTD., RTW INNOVATION MASTER FUND, LTD., and RTW BIOTECH OPPORTUNITIES OPERATING LTD Dated as of October 30, 2024Revenue Interest Financing Agreement • November 4th, 2024 • Allurion Technologies, Inc. • Surgical & medical instruments & apparatus • New York
This Revenue Interest Financing Agreement (this “Agreement”) dated as of October 30, 2024 (the “Closing Date”) is among Allurion Technologies, LLC, a Delaware limited liability company (the “Company”), and RTW Master Fund, Ltd., an exempted company incorporated in the Cayman Islands with limited liability, RTW Innovation Master Fund, Ltd., an exempted company incorporated in the Cayman Islands with limited liability, and RTW Biotech Opportunities Operating Ltd, an investment company limited by shares incorporated under the laws of Guernsey (each and collectively, the “Investor”). Each of the Company and the Investor is referred to in this Agreement as a “Party” and collectively as the “Parties”.
REVENUE INTEREST FINANCING AGREEMENT Dated as of August 4, 2020 between ATHENEX, INC. and SAGARD HEALTHCARE ROYALTY PARTNERS, LPRevenue Interest Financing Agreement • August 6th, 2020 • Athenex, Inc. • Pharmaceutical preparations • New York
This REVENUE INTEREST FINANCING AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of August 4, 2020, by and between Athenex, Inc., a Delaware corporation (the “Company”), and Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempted limited partnership (“Purchaser”, and together with the Company, “Parties”, and each a “Party”).
OMNIBUS AMENDMENTRevenue Interest Financing Agreement • April 17th, 2024 • Allurion Technologies, Inc. • Surgical & medical instruments & apparatus • New York
This Omnibus Amendment (this “Amendment”), dated as of April 14, 2024, is among 4010 Royalty Investments ICAV, an Irish collective asset-management vehicle, for and on behalf of its sub-fund, 4010 Royalty Investments Fund 1, and 4010 Royalty Master Fund, LP, a Cayman Islands limited partnership (each and collectively, together with its and their successors and permitted assigns, the “Investor”), Allurion Technologies, LLC, a Delaware limited liability company (the “Company”), Allurion Technologies, Inc., a Delaware corporation (formerly known as Allurion Technologies Holdings, Inc.) (“Parent”), Allurion Australia Pty Ltd, a proprietary limited company organized under the laws of Australia (“Allurion Australia”), and RTW Investments, LP, as agent for the Investor (in such capacity, together with its successors and permitted assigns, the “Agent”). Each of the Company, Parent, Allurion Australia, the Investor and the Agent is referred to in this Amendment as a “Party” and collectively as
FIRST AMENDMENT TO REVENUE INTEREST FINANCING AGREEMENTRevenue Interest Financing Agreement • May 9th, 2023 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Revenue Interest Financing Agreement (this “Amendment”) is made as of August 4, 2022, by and among BIOXCEL THERAPEUTICS, INC., a Delaware corporation (the “Company”), the purchasers party hereto (collectively, the “Purchasers” and individually, a “Purchaser”) and OAKTREE FUND ADMINISTRATION, LLC, as administrative agent on behalf of the Purchasers (in such capacity, together with its successors and assigns, the “Administrative Agent”).
Revenue Interest Financing AgreementRevenue Interest Financing Agreement • February 27th, 2023 • Fibrogen Inc • Pharmaceutical preparations • New York
This Revenue Interest Financing Agreement (this “Agreement”) is entered into as of November 4, 2022 (the “Effective Date”), between FibroGen, Inc., a Delaware corporation having an address of 409 Illinois Street, San Francisco, CA 94158 (“Company”) and NQ Project Phoebus, L.P., a Delaware limited partnership having an address of 4208 Six Forks Road, Suite 920 Raleigh, NC 27609 (“NovaQuest”). Company and NovaQuest are each referred to herein by name or, individually, as a “Party” or, collectively, as “Parties.”
REVENUE INTEREST FINANCING AGREEMENT by and among LIQUIDIA TECHNOLOGIES, INC., as the Company, HEALTHCARE ROYALTY PARTNERS IV, L.P., as the Investor and HCR COLLATERAL MANAGEMENT, LLC, as the Investor Representative Dated January 9, 2023Revenue Interest Financing Agreement • March 20th, 2023 • Liquidia Corp • Pharmaceutical preparations • New York
This REVENUE INTEREST FINANCING AGREEMENT (this “Agreement”) dated as of January 9, 2023 (the “Effective Date”), is by and among LIQUIDIA TECHNOLOGIES, INC., a Delaware corporation (the “Company”), HEALTHCARE ROYALTY PARTNERS IV, L.P., a Delaware limited partnership (the “Investor”), and HCR COLLATERAL MANAGEMENT, LLC, a Delaware limited liability company (the “Investor Representative”), solely in its capacity as agent for, and representative of, the Investor. Each of the Company and the Investor are referred to in this Agreement as a “Party” and, collectively, as the “Parties”.
REVENUE INTEREST FINANCING AGREEMENT by and between MARINUS PHARMACEUTICALS, INC., as the Company, and SAGARD HEALTHCARE ROYALTY PARTNERS, LP, as the Investor Dated October 28, 2022Revenue Interest Financing Agreement • November 7th, 2022 • Marinus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This REVENUE INTEREST FINANCING AGREEMENT (this “Agreement”) dated as of October 28, 2022 is by and between MARINUS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempted limited partnership (the “Investor”). Each of the Company and the Investor are referred to in this Agreement as a “Party” and collectively as the “Parties”.
SECOND AMENDMENT TO REVENUE INTEREST FINANCING AGREEMENTRevenue Interest Financing Agreement • August 2nd, 2023 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • New York
This SECOND AMENDMENT TO REVENUE INTEREST FINANCING AGREEMENT, dated as of August 1, 2023 (this “Amendment”), is by and among KARYOPHARM THERAPEUTICS INC. (the “Company”), KARYOPHARM EUROPE GMBH, HEALTHCARE ROYALTY PARTNERS III, L.P. (“HCRP Fund III”), HEALTHCARE ROYALTY PARTNERS IV, L.P. (“HCRP Fund IV”), HCRP OVERFLOW FUND, L.P. (“HCRP OF”), HCR STAFFORD FUND, L.P. (“Stafford”), HCR CANARY FUND, L.P. (“Canary”), HCR POTOMAC FUND, L.P. (“Potomac”), HCR MOLAG FUND, L.P. (“Molag” and, together with HCRP Fund III, HCRP Fund IV, HCRP OF, Stafford, Canary and Potomac, the “Investors”), HEALTHCARE ROYALTY MANAGEMENT, LLC (the “Investor Representative”), and HCR COLLATERAL MANAGEMENT, LLC (the “Collateral Agent”). Each of the parties hereto is referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this Amendment and not defined herein shall have the meanings assigned to such terms in, or incorporated by reference into, the Agreement (as defined bel
THIRD AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENTRevenue Interest Financing Agreement • August 10th, 2023 • Liquidia Corp • Pharmaceutical preparations
This THIRD AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT (this “Amendment”), dated as of July 27, 2023 (the “Amendment Effective Date”), is entered into by and between Liquidia Technologies, Inc., a Delaware corporation (the “Company”), and Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership, as the sole Investor and Investor Representative under the Agreement (as defined below) (the “Investor Representative”), solely with respect to certain enumerated provisions in the Agreement described herein. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.
Revenue Interest Financing Agreement By and Among Phathom Pharmaceuticals, Inc., as the Company and The Entities Set Forth on Schedule 1.1, as Investors Dated as of May 3, 2022Revenue Interest Financing Agreement • August 2nd, 2022 • Phathom Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This REVENUE INTEREST FINANCING AGREEMENT, dated as of May 3, 2022 (this “Agreement”), is made and entered into by and among Phathom Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the entities set forth on Schedule 1.1 hereto (the “Initial Investors”) and any other entity or entities that become party hereto pursuant to Section 2.1(b)(ii) or Section 2.1(c) (together with the Initial Investors, the “Investors”, and each, individually, an “Investor”).
FIRST AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENTRevenue Interest Financing Agreement • May 8th, 2023 • Liquidia Corp • Pharmaceutical preparations
This FIRST AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT, dated as of April 17, 2023 (this “Amendment”), is entered into by and among Liquidia Technologies, Inc., a Delaware corporation (the “Company”), Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership (the “Investor”), and HCR Collateral Management, LLC, a Delaware limited liability company (the “Investor Representative”), and solely in its capacity as agent for, and representative of, the Investor, solely with respect to certain enumerated provisions in the Agreement (as defined below) described herein. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.
